Mark me down for $3.85  ,  

If we get great  Secondary endpoints indications on CKD  and great MACE RRR on the sub analysis populations that are statistically significant, We need Dr Kausik Ray to make the best possible positive announcement without focussing on the top line Primary endpoint failure, If a spin is needed so be it,  Focusiing on the good hopeful  data rather than the top line failure,  RVX  could use  some really good media attention to the positive side of the data,  I really think RVX business side has to take this to a new level  if data is great on everything other than top line data